What You Should Know:
- Ontada, McKesson’s oncology and insights business, announced a strategic agreement with Merck, known as MSD outside the United States and Canada, that will facilitate the development of real-world research excellence and innovation. This agreement enables the two healthcare leaders to harness the power of real-world evidence (RWE) towards the common goal of improving patient outcomes and the quality of cancer care.
- Ontada and Merck’s combined experience and
Read More
Real World Evidence (RWE)
Vivalink Launches RWE Biometrics Data Platform
What You Should Know:
- Vivalink, a provider of digital healthcare solutions for real-world evidence data, announced the launch of its enhanced Biometrics Data Platform to accelerate the development and deployment of patient monitoring and data analysis applications for ambulatory and remote settings. Vivalink’s Biometrics Data Platform completes the company’s end-to-end solution that includes both advanced data services as well as medical wearable sensors.
The Biometrics Data Platform
Read More
U of Chicago Med & COTA to Address Racial Disparities in Cancer Using RWD
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company and the University of Chicago Medicine announced a research collaboration agreement to investigate racial disparities of care in multiple myeloma to better understand differences in the diagnosis, treatment patterns, and outcomes of patients with this type of cancer.
- Multiple myeloma is the second-most-common hematologic malignancy, with an estimated 34,920 new cases and 12,410 deaths expected to occur
Read More
Aetion Closes $100M to Expand RWE Analytics Platform
What You Should Know:
- Healthcare technology company Aetion announced today a $110M Series C fundraise, led by Warburg Pincus, a leading global growth equity firm, with additional investments from B Capital and Foresite Capital. Aetion’s existing backers New Enterprise Associates (NEA) and Flare Capital Partners also joined the round. Aetion has raised a total of $212M to date.
- The company will use the new funds to extend the capabilities of its Aetion Evidence Platform, expand its
Read More
Carevive, COS Ink Partnership to Improve Cancer Care with RWE
What You Should Know:
- Carevive and Clinical Outcome Solutions (COS) announced a new partnership to improve the cancer patient experience using RWE and RWD. The partnership will leverage Carevive’s innovative digital oncology platform to capture the patient experience, and COS’ deep experience in analyzing data, ultimately providing valuable insights for life science companies and regulators alike.
- The Carevive platform PROmpt enables cancer care teams to monitor and manage
Read More
Syapse Lands $68M to Expand Global Precision Oncology Data Sharing Network
What You Should Know:
- Syapse raises 68M in equity investment led by Ally Bridge Group (ABG), with Northpond Ventures to expand delivery of real-world evidence through Syapse’s Learning Health Network.
- The Syapse Learning Health Network is a global precision oncology data sharing network, improving cancer care across communities by using real-world data to support clinical decisions.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the delivery
Read More
FDA, Syapse Expand Research to Generate Real-World Data Related to COVID-19 and Cancer
What You Should Know:
The FDA and Syapse announce research collaboration expansion
to address urgent public health challenges including supporting FDA’s goal of
rapid understanding of COVID-19.
As part of the research, Syapse is partnering with FDA’s
Oncology Center of Excellence to investigate methods to derive RWD from
multiple sources including electronic health records, registries and molecular
data
Syapse, a real-world
evidence company accelerating the delivery of precision
Read More
Syapse Lands $30M to Accelerate Real-World Evidence in Oncology
What You Should Know:
- Syapse raises $30M in new equity funding to enable healthcare providers to deliver the best care to every cancer patient through precision medicine.
- Syapse partners with health systems, life sciences companies, and regulators to deliver clinical, programmatic, and research insights from the world’s largest network of health systems focused on precision medicine.
Syapse, a San
Francisco, CA-based provider of precision oncology
solutions announced $30
Read More
Aetion, IBM Watson Health Co-Develop Solution for Conducting Regulatory-Grade RWE Analysis
- IBM Watson Health and Aetion will combine the Aetion Evidence Platform with IBM MarketScan data to provide a turn-key solution for conducting regulatory-grade RWE analysis. - The partnership will satisfy mid-market companies’ demand to streamline the drug R&D process and will allow RWE to play a much greater role in support of companies’ drug portfolios. RWE can enable researchers to supplement clinical trials by optimizing the development of treatments, determining new indications for
Read More
McKesson, Aetion Partner on Real-World Evidence (RWE) in Cancer Research
- Aetion and McKesson announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research. - Relationship pairs Aetion Evidence Platform and McKesson’s robust oncology data sets to accelerate regulatory-grade oncology studiesAetion and McKesson, today announced a strategic collaboration focused on advancing the use of real-world evidence (RWE) in cancer research to benefit patients, regulators, the biopharma industry, and payers. The partnership will
Read More
